Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1979 2
1980 1
1981 1
1984 2
1985 1
1986 1
1987 4
1988 2
1989 2
1990 2
1991 3
1992 3
1993 7
1994 8
1995 10
1996 7
1997 18
1998 7
1999 10
2000 10
2001 14
2002 18
2003 14
2004 10
2005 12
2006 11
2007 17
2008 15
2009 18
2010 18
2011 10
2012 21
2013 20
2014 15
2015 20
2016 13
2017 13
2018 8
2019 24
2020 41
2021 36
2022 52
2023 36
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

520 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Unresectable Lung Small Cell Carcinoma"
Page 1
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR. Duma N, et al. Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. Mayo Clin Proc. 2019. PMID: 31378236 Review.
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. . …
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made …
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Mamdani H, et al. Front Immunol. 2022 Feb 9;13:823618. doi: 10.3389/fimmu.2022.823618. eCollection 2022. Front Immunol. 2022. PMID: 35222404 Free PMC article. Review.
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable …
Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC …
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL. Cortiula F, et al. Ann Oncol. 2022 Sep;33(9):893-908. doi: 10.1016/j.annonc.2022.06.013. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777706 Free article. Review.
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. ...In this review, we present the results of clinical trials investigating immune therapy in …
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CC …
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sánchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Garassino MC, et al. J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub 2022 Aug 9. J Thorac Oncol. 2022. PMID: 35961520 Free article. Clinical Trial.
INTRODUCTION: On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). ...CONCLUSIONS: Durvalumab after sCRT …
INTRODUCTION: On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stag …
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H. Bradley JD, et al. J Clin Oncol. 2020 Mar 1;38(7):706-714. doi: 10.1200/JCO.19.01162. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841363 Free PMC article. Clinical Trial.
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). METHODS: The study used a 2 2 factorial design …
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the …
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Perez BA, Boothman AM, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ, Faivre-Finn C. Paz-Ares L, et al. Ann Oncol. 2020 Jun;31(6):798-806. doi: 10.1016/j.annonc.2020.03.287. Epub 2020 Mar 21. Ann Oncol. 2020. PMID: 32209338 Free PMC article.
BACKGROUND: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after …
BACKGROUND: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with mana …
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC. Senan S, et al. Clin Lung Cancer. 2020 Mar;21(2):e84-e88. doi: 10.1016/j.cllc.2019.12.006. Epub 2019 Dec 28. Clin Lung Cancer. 2020. PMID: 31948903 Free article. Clinical Trial.
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care therapy comprises curative-intent platinum-based chemotherapy with concurrent radiotherapy (cCRT), which can be followed by prophylactic brain ir …
Limited-stage (LS) small-cell lung cancer (SCLC) remains an area of high unmet medical need. The standard-of-care thera …
Management of centrally located non-small-cell carcinoma.
Backhus LM, Wood DE. Backhus LM, et al. Oncology (Williston Park). 2014 Mar;28(3):215-21. Oncology (Williston Park). 2014. PMID: 24855729 Free article. Review.
Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient selection. ...Therefore, other modalities are often necessary to complete the clinical staging. In the absence of irrefutable evidence of …
Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient s …
Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?
Sun TY, Hendifar A, Padda SK. Sun TY, et al. Curr Oncol Rep. 2022 Jul;24(7):819-824. doi: 10.1007/s11912-022-01253-9. Epub 2022 Mar 19. Curr Oncol Rep. 2022. PMID: 35305210 Review.
PURPOSE OF REVIEW: Lung neuroendocrine tumors (NETs)-typical carcinoids and atypical carcinoids-have unique molecular alterations that are distinct from neuroendocrine carcinomas of the lung and non-small cell lung cancers. ...Previous findings …
PURPOSE OF REVIEW: Lung neuroendocrine tumors (NETs)-typical carcinoids and atypical carcinoids-have unique molecular alterations tha …
Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM, Tsuboi M, Brunelli A. Lee JM, et al. Ann Thorac Surg. 2022 Oct;114(4):1505-1515. doi: 10.1016/j.athoracsur.2021.06.069. Epub 2021 Jul 30. Ann Thorac Surg. 2022. PMID: 34339672 Free article. Review.
BACKGROUND: With a 5% improvement in 5-year overall survival achieved with current neoadjuvant or adjuvant chemotherapy, new treatments for resectable non-small cell lung cancer (NSCLC) are urgently needed. The use of immune checkpoint inhibitors (ICIs) is es …
BACKGROUND: With a 5% improvement in 5-year overall survival achieved with current neoadjuvant or adjuvant chemotherapy, new treatments for …
520 results